Considering the fact that the mortality rate of dialysisdependent acute renal failure continues to remain at 50%, it is understandable that nephrologists time and again investigate whether the blood-cleansing procedures available to them can be modified to reduce the mortality level. Various steps have been taken in the past in this regard, none of which, however, has had a significant influence on the survival of these patients. Continuous dialysis procedures have been compared with intermittent procedures, convective substance transport and diffusive elimination carefully evaluated with respect to their influence on the survival rate of patients with acute renal failure. Recently a further parameter has taken its place at the center of therapeutic strategies -the dialysis membrane. Two publications have reported that the use of a biocompatible dialysis membrane not only more quickly leads to a recovery of renal function, but that these patients more frequently survive than those treated with a bioincompatible cuprophane membrane (1, 2) . Both of these articles have been discussed at congresses and in editorials in journals and have already led to therapeutic recommendations from medical societies. However, in both cases, careful analysis of the data shows that the claims are not supported by proven results. Particularly with respect to the biometrics, the planning and execution of the study exhibits considerable flaws.
The reservations about the optimistic assessments forwarded in the two studies, however, results also from the fact that the clinical picture -or better, the syndrome of the acute renal failure -is so heterogenous and multifactorial. It is difficult to imagine that the (short-term) change of only one factor (in this case the membrane), could significantly influence to the degree described. This suspicion is founded on the fact that in 34 different works the survival rate of patients that suffered renal failure, who had been intermittently dialyzed with bioincompatible membranes, varied between 12 and 68% (3). The survival rates of continuously dialysized patients (with biocompatible membranes) were about the same, between 16 and 63% (3). And finally there was a survival rate of between 10 and 76% with the exclusive use of peritoneal dialysis (3).
The acceptance of a significant importance of the biocompatibility (or better hemocompatibility) of the dialysis membrane for the prognosis of an acute renal failure is made even more difficult by our own investigational results, because the application of a biocompatible membrane did not influence either the mortality or the number of dialysis necessary for the recovery of the renal function (4). Interestingly, despite comparable patients, the same survival rates were attained with biocompatible and bioincompatible membranes as were attained in both of the other studies only with the use of biocompatible membranes (4) .
Various questions arise from these varying results. Questions which any physician with knowledge of the literature, years of working with dialysis and intensive medical experience would be forced to raise:
1) Why do so many patients treated with bioincompatible membranes in the study by Hakim et al die (63%), although the causes of the acute renal failure are partially benign?
2) How is an Apache " score of 28 ± 8 possible (1), although the patients had many more benign causes for their acute renal failure?
3 First of all there is the physician's understandable desire to reduce the high lethality of acute renal failure. The theoretic advantages of biocompatible membranes will promote the use of corresponding dialysators. Commercial interest will lead to the influence of manufacturers. In general it can be said that false positive judgements about the efficacy of a therapeutic intervention are more persistent and difficult to correct than are false negative ones. This is primarily due to a clearly possitive judgement of a therapy -as confirmed here by the case with the mistaken superiority of the biocompatible membrane to that of a standard therapy which makes a review more difficult simply by being stated. This is an example of medicine's pronounced and characteristic tendency to dogma. If there were one other study with comparable methods that had led to the opposite results, the question would be raised as to how the physicians should behave in such a situation. Do they stick to the traditional therapy or turn to the new method? The need for prestige, authority and maybe courage will be the crux of their decision. At present, clinical competence and experience, continual medical care and well-trained personnel are of more importance for the treatment of acute renal failure than the choice of membrane. Acute renal failure is frequently the consequence of grave illness, the control of which must be the primary concern of all involved in the care of the patient. The problem raises other 146 questions. The premature publication of insufficiently proven results has already established a fait accompli in this case. A study which could clearly repudiate the results of Hakim et al and Schiffl et al (an equivalence study) would be very difficult, very expensive and again subject patients to a study situation. This is questionable from an ethical standpoint. The publication of insufficiently proven results, which in no way represents an exception in medical publishing, may be the real reason for the therapeutic dilemma many nephrologists are confronted with. Should it not be expected that scientific research which has such serious therapeutic implications as those of Hakim et al and Schiffl et al be particularly carefully evaluated with respect to their ethical implications? Should not the biometric flaws be eliminated before hand and care be given that the planning and execution of such studies is proper? It is possible as well to raise the question as to the possible role of ethical committees. Is it important that not only the execution of investigations in patients meets ethical standards, but equally so that the study results be carefully discussed by ethical committees with respect to their effects, before they are published and therefore become even more difficult to correct?
